Is Interparfums (IPAR) Undervalued After Its PUMA Fragrance Licensing Deal?

Interparfums (IPAR) just expanded its licensing portfolio again, signing an exclusive worldwide deal to create and distribute PUMA branded fragrances through 2037, with the first launch slated for 2027.

Against that backdrop, Interparfums has been enjoying strong momentum, with a year to date share price return of 38.03% and a 1-year total shareholder return of 20.45%, even as a 3-year total shareholder return that declined 4.75% reminds investors how quickly sentiment can shift.

Scan how Interparfums’ latest licensing moves compare with other consumer brands building long-run fragrance and beauty franchises through our hand picked 16 high quality undiscovered gems.

Interparfums now trades about 7% below the average analyst target and roughly 50% below one intrinsic value estimate. Is that caution about margin pressure sensible, or is the PUMA deal being underpriced?

Most Popular Narrative: 7% Undervalued

Interparfums is pegged with a fair value of $126.67 against the last close at $117.93. The widely followed narrative sketches in some upside but leans heavily on how durable the licensing model really is.

Ongoing portfolio expansion with prestigious fragrance licenses (e.g., recent additions like Longchamp and growth with Lacoste and Solférino) enhances brand diversity and secures access to rising demand for premium and experiential luxury products, supporting future top-line growth and earnings stability. Proactive supply chain optimization (e.g., localizing production, diversifying sourcing away from China, shifting to third-party logistics) is expected to increase operational efficiency and reduce tariff and logistics risks, leading to improved gross and operating margins over the long term.

See why 8 investors see Interparfums as 7% undervalued.

Result: Fair Value of $126.67 (UNDERVALUED)

Still, the Interparfums story can break if key licenses underperform or are not renewed, or if retailer destocking continues to pressure reported earnings and visibility.

Find out about the key risks to this Interparfums narrative.

Next Steps

Mixed signals on Interparfums and its licensing pipeline can cut both ways, so move quickly, review the full picture, and weigh the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Interparfums?

If Interparfums has sharpened your focus on quality, do not stop here. Use targeted screeners to surface other opportunities that might fit your approach.

• Spot potential mispricings early and review our hand picked 32 high quality undervalued stocks before the rest of the market catches on.
• Prioritize resilience in choppy conditions and sift through a 30 resilient stocks with low risk scores that filters for sturdier business profiles.
• Target companies with healthier finances and scan the list of solid balance sheet and fundamentals (24 results) to support a more robust watchlist.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com